WHAT IS CLAIMED IS:

- 1. A composition comprising:
- demineralized bone matrix (DBM); and
- a collagen protein;
- 5 wherein the composition is cross-linked.
 - 2. The composition of Claim 1, wherein the composition is chemically crosslinked with a carbodiimide crosslinking agent.
 - 3. The composition of Claim 2, wherein the carbodiimide crosslinking agent is N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC).
- 4. The composition of Claim 2, wherein the composition is chemically cross-linked in the presence of N-hydroxysuccinimide (NHS).
 - 5. The composition of Claim 1, further comprising one or more growth factors.
- 6. The composition of Claim 1, wherein the composition comprises from 2 to 95 wt/% DBM.
 - 7. The composition of Claim 1, wherein the composition comprises from 55 to 85 wt/% DBM.
 - 8. The composition of Claim 1, wherein the DBM comprises particles of the DBM dispersed in the collagen.
- 9. The composition of Claim 1, wherein the collagen protein is in a porous scaffolding.
 - 10. The composition of Claim 9, wherein the DBM comprises particles of DBM dispersed in the porous scaffolding.

- 11. The composition of Claim 8, wherein the DBM particles have an average particle size of up to 5 mm.
- 12. The composition of Claim 8, wherein the DBM particles have an average particle size ranging from 53 to 850 μm .
- 13. The composition of Claim 1, wherein the composition is chemically crosslinked with a compound selected from the group consisting of gluteraldehyde, formaldehyde, 1,4-butanediol diglycidyl ether, hydroxypyridinium, hydroxylysylpyridinium, and formalin.
 - 14. The composition of Claim 1, wherein the composition is crosslinked by irradiation.

10

15

20

- 15. The composition of Claim 1, wherein the composition is crosslinked by photooxidation.
- 16. The composition of Claim 1, wherein the composition is crosslinked via an enzymatic process.
- 17. The composition of Claim 16, wherein the collagen protein is crosslinked via the action of tissue transglutaminase.
 - 18. The composition of Claim 16, wherein the composition is crosslinked with lysyl oxidase.
- 19. The composition of Claim 1, wherein the composition is crosslinked by a dehydrothermal treatment.
 - 20. The composition of Claim 1, wherein the composition is crosslinked under acidic conditions.
 - 21. The composition of Claim 1, wherein the collagen protein is

crosslinked using e-beam irradiation, gamma irradiation, or light.

- 22. The composition of Claim 21, wherein the collagen protein is crosslinked using pulsed light.
 - 23. The composition of Claim 1, further comprising a spacer.
- 5 24. The composition of Claim 23, wherein the spacer is a polyoxyalkyleneamine spacer or a polyethylene glycol spacer.

10

15

- 25. The composition of Claim 1, wherein the composition further comprises vinyl pyrrolidinone or methyl methacrylate.
- 26. The composition of Claim 1, further comprising an additive selected from the group consisting of collagenase inhibitors, growth factors, antibodies, metalloproteinases, cell attachment fragment(s), and combinations thereof.
- 27. The composition of Claim 26, wherein the additive is bound to the collagen or DBM.
- 28. The composition of Claim 26, wherein the additive is not bound to the collagen or DBM.
 - 29. The composition of Claim 1, wherein the composition is crosslinked by glycation or glycosylation.
 - 30. The composition of Claim 1, wherein the crosslinks are pentosidine crosslinks.
- 20 31. The composition of Claim 1, wherein the crosslinks are epsilon(gamma-glutamyl)lysine crosslinks.
 - 32. A method of making a composition comprising a collagen protein and demineralized bone matrix, the method comprising:

crosslinking the composition.

10

15

20

- 33. The method of Claim 32, wherein the composition is chemically crosslinked with a carbodiimide crosslinking agent.
 - 34. The method of Claim 33, wherein the carbodiimide is N-(3-
- 5 dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC).
 - 35. The method of Claim 33, wherein the composition is chemically cross-linked in the presence of N-hydroxysuccinimide (NHS).
 - 36. The method of Claim 35, wherein the NHS is present at an EDC/NHS ratio of 1:2 to 2:5.
 - 37. The method of Claim 35, wherein the NHS is present at an EDC/NHS ratio of 1:2, 2:3 or 2:5.
 - 38. The method of Claim 32, further comprising dispersing particles of the demineralized bone matrix in a collagen slurry, casting the slurry into the cavity of a mold and freeze drying the cast slurry to form a porous scaffolding comprising the collagen protein and particles of the demineralized bone matrix.
 - 39. The method of Claim 38, wherein the slurry is an aqueous slurry.
 - 40. The method of Claim 38, wherein crosslinking comprises:

infiltrating a carbodiimide crosslinking agent into pores of the porous scaffolding; and

- allowing the carbodiimide cross-linking agent to react with the collagen protein and/or the DBM to form cross-links.
- 41. The composition of Claim 32, wherein the crosslinking results from culturing a non-crosslinked matrix *in vivo* to allow collagen crosslinking by

cellular mechanisms.

- 42. A method of treatment comprising implanting a composition comprising demineralized bone matrix (DBM) and a collagen protein into a mammal, wherein the composition is crosslinked.
- 5 43. The method of Claim 42, wherein the composition is chemically crosslinked with a carbodiimide crosslinking agent.
 - 44. The method of Claim 42, wherein the composition is implanted into the spine of the mammal.
- 45. The method of Claim 42, wherein the composition is implanted into an intervertebral space of the mammal.
 - 46. The method of Claim 42, wherein the composition is implanted into the site of a trauma injury.
 - 47. The method of Claim 42, wherein the composition is implanted into a craniomaxillofacial cavity.
 - 48. The method of Claim 42, wherein the mammal is a human.
 - 49. A composition comprising:

demineralized bone matrix (DBM); and

a collagen protein;

15

20

wherein the composition is cross-linked via an amide linkage.

- 50. The composition of Claim 49, further comprising one or more growth factors.
- 51. The composition of Claim 49, wherein the composition comprises from 2 to 95 wt/% DBM.

- 52. The composition of Claim 49, wherein the composition comprises from 55 to 85 wt/% DBM.
- 53. The composition of Claim 49, wherein the composition comprises particles of the DBM dispersed in the collagen protein.
- 5 54. The composition of Claim 49, wherein the collagen protein is in a porous scaffolding.
 - 55. The composition of Claim 54, wherein the composition comprises particles of the DBM dispersed in the porous scaffolding.
- 56. The composition of Claim 55, wherein the DBM particles have aparticle size of up to 5 mm.
 - 57. The composition of Claim 55, wherein the DBM particles have a particle size of from 53 to 850 μm .